Ze Jing Biology: Injection ZG005 approved for clinical trials in combination with Gefitinib Hydrochloride Tablets and chemotherapy.

Recently, Suzhou Zejing Biopharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of ZG005 for injection in combination with Gefitinib Hydrochloride Tablets and chemotherapy for advanced solid tumors. ZG005 for injection is an innovative tumor immunotherapy biological product, which is expected to treat various solid tumors; Gefitinib Hydrochloride Tablets is a new type of JAK and ACVR1 dual inhibitor drug, with some indications already approved or under review. However, drug development has a long cycle and many steps, leading to uncertainties. The approval will not have a significant impact on the company's recent performance, and investors are reminded to pay attention to risks.